Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Mersana Therapeutics has started Phase 1b extension study of cancer drug XMT-1001 in second-line gastric cancer and second-/third-line non-small cell lung cancer.
Subscribe to our email newsletter
Earlier, Mersana Therapeutics has released data from a Phase 1 trial evaluating XMT-1001, which showed high and prolonged plasma levels of XMT-1001 active release products and a safety profile free of the toxicities normally associated with topoisomerase 1 inhibitors, such as hemorrhagic cystitis and diarrhea.
The product showed evidence of clinical activity, including tumor shrinkage and prolonged stable disease, in a heavily pre-treated patient population.
Mersana Therapeutics CEO Nick Bacopoulos said their recently completed Phase 1 study has confirmed the potential efficacy and safety advantages of the unique design of their lead Fleximer conjugate, XMT-1001.
Phase 1b study principal investigator Edward Sausville said their clinical experience with XMT-1001 to date suggests that it can be safely given up to doses limited by its mechanism, and thus may be useful in maximizing the therapeutic potential of its class.